Jaguar HealthFRA:1JA1 22 ROE % is Negative Equity% as of Mar. 2026. GuruFocus rates FRA:1JA1 with a GF Score™ of 22/100. The stock has 3 warning signs investors should review. Among 1,255 Biotechnology companies, Jaguar Health ranks worse than 79681.2% on this metric.
ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Jaguar Health's annualized net income for the quarter that ended in Mar. 2026 was €30.62 Mil. Jaguar Health's average Total Stockholders Equity over the quarter that ended in Mar. 2026 was €-13.51 Mil. Therefore, Jaguar Health's annualized ROE % for the quarter that ended in Mar. 2026 was Negative Equity%.
The historical rank and industry rank for Jaguar Health's ROE % or its related term are showing as below:
FRA:1JA1's ROE % is not ranked *
in the Biotechnology industry.
Industry Median: -38.18 * Ranked among companies with meaningful ROE % only.
Jaguar Health (FRA:1JA1) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Jaguar Health ROE % Related Terms
Jaguar Health ROE % Historical Data
* Premium members only.
The historical data trend for Jaguar Health's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Jaguar Health's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jaguar Health ROE % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Jaguar Health's ROE % distribution charts can be found below:
* The bar in red indicates where Jaguar Health's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
* Note that if the average Total Stockholders Equity is zero or negative, then ROE % would be considered meaningless and hence not be calculated.
Jaguar Health (FRA:1JA1) has a ROE % of Negative Equity% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Jaguar Health and its competitors. According to the industry distribution chart, Jaguar Health ranks #999999 out of 1255 companies in the Biotechnology industry.
Is Jaguar Health's ROE % too high?
Jaguar Health's current ROE % is Negative Equity%. Based on the distribution chart, Jaguar Health ranks #999999 out of 1255 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Jaguar Health has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Jaguar Health's ROE % compare to BBLG and VBIO?
According to the Biotechnology industry distribution chart, Jaguar Health ranks #999999 out of 1255 companies for ROE %. This places Jaguar Health in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Biotechnology company?
A good ROE % depends on the Biotechnology industry context. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Jaguar Health and its competitors. Jaguar Health's current ROE % is Negative Equity%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jaguar Health stock overvalued right now?
Jaguar Health (FRA:1JA1) has a current ROE % of Negative Equity%. The current ROE % is Negative Equity%. Jaguar Health's overall GF Score™ is 22/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Jaguar Health (FRA:1JA1), the current ROE % is Negative Equity% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Jaguar Health Inc is a commercial-stage pharmaceutical company developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for gastrointestinal disease states in humans and animals. The Company focuses on conditions associated with overactive bowel, including chronic debilitating diarrhea, urgency, and bowel incontinence. It operates through two segments: animal health, which develops and commercializes products for animals, and human health, with the human health segment generating the maximum revenue and focusing on products such as Mytesi, focusing on human products, specifically Mytesi, approved for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.
22GF Score
Get the complete analysis for FRA:1JA1
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:1JA1 has been successfully added to your 
